πŸ‡ΊπŸ‡Έ FDA
Patent

US 7820154

Use of IL-1 antagonists to treat gout

granted A61KA61K31/195A61K31/216

Quick answer

US patent 7820154 (Use of IL-1 antagonists to treat gout) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/195, A61K31/216, A61K31/343, A61K31/4152